0.1625

8.41% 0.0127

After Hours: .16 -0.00245 -1.51%

Calidi Biotherapeutics Inc (CLDI)

Overview News Price History Discussions Forecast

Calidi Biotherapeutics Inc stock is traded at $0.1625, with a volume of 17.18M. It is up +8.41% in the last 24 hours and down -8.35% over the past month. Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.

Previous Close:

$0.1498

Open:

$0.1467

24h Volume:

17.18M

Relative Volume:

3.28

Market Cap:

$3.14M

Revenue:

Net Income/Loss:

$-25.09M

P/E Ratio:

-0.0313

EPS:

-5.1824

Net Cash Flow:

$-18.40M

1W Performance:

-3.85%

1M Performance:

-8.35%

6M Performance:

-86.90%

1Y Performance:

-94.09%

1-Day Range:

$0.1456

$0.1871

1-Week Range:

$0.1443

$0.1871

52-Week Range:

$0.1201

$19.20

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Name

Calidi Biotherapeutics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (619)

Phone

(858) 794-9600

Address

4475 Executive Drive, Suite 200, San Diego

Employee

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

CLDI's Discussions on Twitter

Compare CLDI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLDI Calidi Biotherapeutics Inc	0.1624	2.89M	0	-25.09M	-18.40M	-5.1824
VRTX Vertex Pharmaceuticals Inc	490.70	121.87B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	632.90	65.01B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	887.17	55.26B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.48	39.14B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	182.08	37.88B	742.00K	-1.37B	-1.07B	-7.0731

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-22-23	Initiated	H.C. Wainwright	Buy
Oct-09-23	Initiated	Robert W. Baird	Outperform

Calidi Biotherapeutics Inc Stock (CLDI) Latest News

06:28 AM

Calidi Biotherapeutics, Inc. Actuals & Estimates (AMEX:CLDI) - TradingView

06:28 AM

Jun 24, 2026

Calidi’s tumor-targeted T-cell approach aims at hard-to-hit solid tumors - Stock Titan

Jun 24, 2026

Jun 23, 2026

Form 8K Calidi Biotherapeutics Inc For: 23 June By Investing.com - Investing.com Australia

Jun 23, 2026

Form 8K Calidi Biotherapeutics Inc For: 23 June - Investing.com UK

Jun 23, 2026

Calidi Biotherapeutics Expands Board With New Independent Director - TipRanks

Jun 23, 2026

Calidi Biotherapeutics Appoints Industry Veteran Corsee Sanders, Ph.D., to Board of Directors to Advance RedTail Platform and CLD-401 Clinical Development – Minichart - Minichart

Jun 23, 2026

Calidi Biotherapeutics appoints Corsee Sanders to board - Investing.com

Jun 23, 2026

Industry veteran Corsee Sanders joins Calidi Biotherapeutics (CLDI) board and Audit Committee - Stock Titan

Jun 23, 2026

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - The Manila Times

Jun 23, 2026

Press Release: Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - Moomoo

Jun 23, 2026

Calidi Biotherapeutics Appoints Former Genentech/Roche and - GlobeNewswire

Jun 23, 2026

Jun 22, 2026